MedTrace Logo

Safety Study of FLP Injection to Treat Tumor Patients

NCT01361529 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-05-27

No results posted yet for this study

Summary

The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for FLP Injection with multiple dose in tumor patients.

Conditions

Interventions

DRUG

FLP,dose escalation,MTD

dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle

Sponsors & Collaborators

  • Acea Bio (Hangzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • jianying zhou, professor · First Affiliated Hospital of Zhejiang University

  • nong xu, professor · First Affiliated Hospital of Zhejiang University

  • jianzhong shentu, professor · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361529 on ClinicalTrials.gov